{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".2","upperLimit":".05","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.","groups":[{"description":"100 mg orally twice daily","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","populationDescription":"Analysis per protocol.","timeFrame":"At 12-weeks","title":"Number of Participants With Progression-free Survival at 12-weeks","type":"PRIMARY","unitOfMeasure":"participants"}